James E. Loyd

James E. Loyd

Auto-generated profile, based on publicly available information

James E. Loyd

Vanderbilt University Medical Center, Nashville, Tennessee

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2013 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
WTWilliam D. Travis
William D. Travis
UCUlrich Costabel
Ulrich Costabel
DHDavid M. Hansell
David M. Hansell
TKTalmadge E. King
Talmadge E. King
DLDavid A. Lynch
David A. Lynch
DVDominique Valeyre
Dominique Valeyre
Background: In 2002 the American Thoracic Society/European Respiratory Society (ATS/ERS) classification of idiopathic interstitial pneumonias (IIPs) defined seven specific entities, and provided standardized terminology and diagnostic criteria. In addition, the historical “gold standard” of histologic diagnosis was replaced by a multidisciplinary approach. Since 2002 many publications have provided new information about IIPs. Purpose: The objective of this statement is to update the 2002 ATS/ERS classification of IIPs. Methods: An international multidisciplinary panel was formed and developed key questions that were addressed through a review of the literature published between 2000 and 2011. Results: Substantial progress has been made in IIPs since the previous classification. Nonspecific interstitial pneumonia is now better defined. Respiratory bronchiolitis–interstitial lung disease is now commonly diagnosed without surgical biopsy. The clinical course of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia is recognized to be heterogeneous. Acute exacerbation of IIPs is now well defined. A substantial percentage of patients with IIP are difficult to classify, often due to mixed patterns of lung injury. A classification based on observed disease behavior is proposed for patients who are difficult to classify or for entities with heterogeneity in clinical course. A group of rare entities, including pleuroparenchymal fibroelastosis and rare histologic patterns, is introduced. The rapidly evolving field of molecular markers is reviewed with the intent of promoting additional investigations that may help in determining diagnosis, and potentially prognosis and treatment. Conclusions: This update is a supplement to the previous 2002 IIP classification document. It outlines advances in the past decade and potential areas for future investigation.

1 September 2000 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
KLKirk B. Lane
Kirk B. Lane
Rajiv MachadoRajiv Machado
Rajiv Machado
MPMichael W. Pauciulo
Michael W. Pauciulo
JTJennifer R. Thomson
Jennifer R. Thomson
JPJohn A. Phillips
John A. Phillips
RTRichard C. Trembath
Richard C. Trembath

29 March 2007 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MAMary Y. Armanios
Mary Y. Armanios
JCJulian J.-L. Chen
Julian J.-L. Chen
JCJoy D. Cogan
Joy D. Cogan
JAJonathan K. Alder
Jonathan K. Alder
RIRoxann G. Ingersoll
Roxann G. Ingersoll
JLJames E. Loyd
James E. Loyd
Idiopathic pulmonary fibrosis is progressive and often fatal; causes of familial clustering of the disease are unknown. Germ-line mutations in the genes hTERT and hTR, encoding telomerase reverse transcriptase and telomerase RNA, respectively, cause autosomal dominant dyskeratosis congenita, a rare hereditary disorder associated with premature death from aplastic anemia and pulmonary fibrosis. To test the hypothesis that familial idiopathic pulmonary fibrosis may be caused by short telomeres, we screened 73 probands from the Vanderbilt Familial Pulmonary Fibrosis Registry for mutations in hTERT and hTR. Six probands (8%) had heterozygous mutations in hTERT or hTR; mutant telomerase resulted in short telomeres. Asymptomatic subjects with mutant telomerase also had short telomeres, suggesting that they may be at risk for the disease. We did not identify any of the classic features of dyskeratosis congenita in five of the six families. Mutations in the genes encoding telomerase components can appear as familial idiopathic pulmonary fibrosis. Our findings support the idea that pathways leading to telomere shortening are involved in the pathogenesis of this disease.

1 October 2007 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
LWL. Joseph J. Wheat
L. Joseph J. Wheat
AFAlison G. Freifeld
Alison G. Freifeld
MKMartin B. Kleiman
Martin B. Kleiman
JBJohn W. Baddley
John W. Baddley
DMDavid S. McKinsey
David S. McKinsey
CKCarol A. Kauffman
Carol A. Kauffman
Evidence-based guidelines for the management of patients with histoplasmosis were prepared by an Expert Panel of the Infectious Diseases Society of America. These updated guidelines replace the previous treatment guidelines published in 2000 (Clin Infect Dis 2000; 30:688–95). The guidelines are intended for use by health care providers who care for patients who either have these infections or may be at risk for them. Since 2000, several new antifungal agents have become available, and clinical trials and case series have increased our understanding of the management of histoplasmosis. Advances in immunosuppressive treatment for inflammatory disorders have created new questions about the approach to prevention and treatment of histoplasmosis. New information, based on publications from the period 1999–2006, are incorporated into this guideline document. In addition, the panel added recommendations for management of histoplasmosis in children for those aspects that differ from aspects in adults.

21 April 2011 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MSMax A. Seibold
Max A. Seibold
AWAnastasia L. Wise
Anastasia L. Wise
MSMarcy C. Speer
Marcy C. Speer
MSMark P. Steele
Mark P. Steele
KBKevin K. Brown
Kevin K. Brown
DSDavid A. Schwartz
David A. Schwartz
The mutations that have been implicated in pulmonary fibrosis account for only a small proportion of the population risk. Using a genomewide linkage scan, we detected linkage between idiopathic interstitial pneumonia and a 3.4-Mb region of chromosome 11p15 in 82 families. We then evaluated genetic variation in this region in gel-forming mucin genes expressed in the lung among 83 subjects with familial interstitial pneumonia, 492 subjects with idiopathic pulmonary fibrosis, and 322 controls. MUC5B expression was assessed in lung tissue. Linkage and fine mapping were used to identify a region of interest on the p-terminus of chromosome 11 that included gel-forming mucin genes. The minor-allele of the single-nucleotide polymorphism (SNP) rs35705950, located 3 kb upstream of the MUC5B transcription start site, was present at a frequency of 34% among subjects with familial interstitial pneumonia, 38% among subjects with idiopathic pulmonary fibrosis, and 9% among controls (allelic association with familial interstitial pneumonia, P=1.2×10−15; allelic association with idiopathic pulmonary fibrosis, P=2.5×10−37). The odds ratios for disease among subjects who were heterozygous and those who were homozygous for the minor allele of this SNP were 6.8 (95% confidence interval [CI], 3.9 to 12.0) and 20.8 (95% CI, 3.8 to 113.7), respectively, for familial interstitial pneumonia and 9.0 (95% CI, 6.2 to 13.1) and 21.8 (95% CI, 5.1 to 93.5), respectively, for idiopathic pulmonary fibrosis. MUC5B expression in the lung was 14.1 times as high in subjects who had idiopathic pulmonary fibrosis as in those who did not (P<0.001). The variant allele of rs35705950 was associated with up-regulation in MUC5B expression in the lung in unaffected subjects (expression was 37.4 times as high as in unaffected subjects homozygous for the wild-type allele, P<0.001). MUC5B protein was expressed in lesions of idiopathic pulmonary fibrosis. A common polymorphism in the promoter of MUC5B is associated with familial interstitial pneumonia and idiopathic pulmonary fibrosis. Our findings suggest that dysregulated MUC5B expression in the lung may be involved in the pathogenesis of pulmonary fibrosis. (Funded by the National Heart, Lung, and Blood Institute and others.)

1 October 2007 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
HCHarold R. Collard
Harold R. Collard
BMBethany B. Moore
Bethany B. Moore
KFKevin R. Flaherty
Kevin R. Flaherty
KBKevin K. Brown
Kevin K. Brown
RKRobert J. Kaner
Robert J. Kaner
TIthe Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators
the Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators
The natural history of idiopathic pulmonary fibrosis (IPF) has been characterized as a steady, predictable decline in lung function over time. Recent evidence suggests that some patients may experience a more precipitous course, with periods of relative stability followed by acute deteriorations in respiratory status. Many of these acute deteriorations are of unknown etiology and have been termed acute exacerbations of IPF. This perspective is the result of an international effort to summarize the current state of knowledge regarding acute exacerbations of IPF. Acute exacerbations of IPF are defined as acute, clinically significant deteriorations of unidentifiable cause in patients with underlying IPF. Proposed diagnostic criteria include subjective worsening over 30 days or less, new bilateral radiographic opacities, and the absence of infection or another identifiable etiology. The potential pathobiological roles of infection, disordered cell biology, coagulation, and genetics are discussed, and future research directions are proposed.